New distribution partner in ANZ for TAP Biosystems
TAP Biosystems has announced the appointment of TrendBio, a supplier of life science research products, as its new distribution partner. The appointment will provide scientists in Australia and New Zealand with rapid access to, and support of, TAP Biosystems’ range of automated bioprocessing and cell processing technologies.
Under the terms of the agreements, TrendBio will exclusively market and support a range of TAP’s products in Australia and New Zealand. These include ambr (automated micro scale bioreactor), which mimics the characteristics of classical bioreactors at micro scale; RAFT (3D cell culture system), which generates consistent, reproducible collagen-based 3D cell cultures for drug screening applications; and Fill-It (automated dispensing into screw-cap cryovials), which maintains optimum cell quality when processing large batches of cryovials.
For scientists who want to see this innovative technology live, TAP is exhibiting at the BioProcessing Network Conference in Melbourne from 16-18 October.
Ian Ransome, TAP Biosystems’ Director of Commercial Operations, Asia Pacific, said: “We are delighted TrendBio is our distribution partner because the company has an excellent reputation for marketing many leading life science equipment brands in Australia and New Zealand. This means scientists here can be assured of professional support for their systems from a dedicated team of technical sales specialists.
“We look forward to meeting scientists at the BioProcessing Network Conference and to discussing how all of the products available through TrendBio will help them to enhance the quality of their research, as well as significantly improve the productivity of their bioprocessing or cell-based research and development programs.”
Professor Tony Haymet appointed Australia's Chief Scientist
Emeritus Professor Tony Haymet — a world-leading oceanographer, chemist and entrepreneur...
NZ announces significant reforms to science sector
The reforms are intended to maximise the value of the $1.2 billion in government funding that...
Vaxxas to advance its microarray patches for COVID vaccination
Vaxxas will receive AU$3.2m from BARDA to accelerate work advancing its high-density microarray...